Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Nucleus Medical GmbH has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 3 distinct examiners across 2 distinct art units. This structure shows a focused technical scope, as the active matters are contained within only 2 art units.
WERTZ, ASHLEE ELIZABETH is the busiest examiner for the portfolio, managing 1 pending office action. With 3 distinct examiners each handling the same number of pending office actions, the company's prosecution workload is evenly distributed. No single examiner has a disproportionate influence on the portfolio's current progress.
The concentration of 3 pending office actions within 2 distinct art units suggests that multiple examiners are likely working within the same or closely related technical fields. For a portfolio in Biotechnology & Pharmaceuticals, this distribution requires attention to the specific nuances of the assigned art units. The 3 distinct examiners provide a variety of perspectives on the company's patent applications, with 1 examiner assigned to each matter.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WERTZ, ASHLEE ELIZABETH | 1 | 52.9% | +42.1% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568694 | NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES | MERCIER, MELISSA S | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17839786 | NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES | LEE, SIN J | 58d overdue |
| 18844505 | TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING A MACROLIDE IMMUNOSUPPRESSANT | WERTZ, ASHLEE ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844505 | TRANSMUCOSAL THERAPEUTIC SYSTEM CONTAINING A MACROLIDE IMMUNOSUPPRESSANT | WERTZ, ASHLEE ELIZABETH | — | §103§112DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18568694 | NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES | MERCIER, MELISSA S | 1615 | §102§103§112 | Final Rejection | 14d | Pending | Dec 08, 2023 |
| 17839786 | NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES | LEE, SIN J | 1613 | §103 | Non-Final OA | 58d overdue | Pending | Jun 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial